BioCentury | Aug 28, 2020
Finance

Turning to solid tumors, cell therapy play Triumvira earns syndicate’s $55M vote of confidence

...Andreas Bader, a co-founder of Mirna who worked alongside Lammers.Early investors included Toronto-based investment bank Bloom Burton...
BioCentury | Sep 5, 2019
Financial News

Sept. 5 Financial Quick Takes: Zealand raises cash as it readies NDA; plus Bellus, Aerie, LNC, Veralox and Sigrid

...offering. Underwriters of the offering, upsized from $60 million, are Jefferies, Cowen, Guggenheim, Baird and Bloom Burton...
BioCentury | Sep 4, 2019
Financial News

Sept. 4 Financial Quick Takes: BrightGene looks to STAR; plus IPO updates from Immunotech, 10x Genomics, SpringWorks, IGM, Satsuma and more

...$60 million via an offering of common shares. Underwriters are Jefferies, Cowen, Guggenheim, Baird and Bloom Burton...
BioCentury | Oct 2, 2018
Company News

Management tracks: Synlogic, Trevena, Editas

...named Armand Balboni as its first CSO. He is a partner at investment advisory firm Bloom Burton. BC...
BioCentury | Dec 15, 2017
Financial News

Bellus Health raises C$20M in follow-on

...at C$0.38 in a follow-on. The price values the company at C$45.4 million ($35.4 million). Bloom Burton...
BioCentury | Jun 23, 2017
Financial News

Antibe closes C$4 million follow-on

...the sale of 40.5 million units at C$0.10 in the first close of a follow-on. Bloom Burton...
BioCentury | Jun 23, 2017
Financial News

Resverlogix completes private placement and overnight marketed equity offering

...sold a further 2.6 million units in a concurrent overnight marketed equity offering underwritten by Bloom Burton...
BioCentury | Mar 17, 2017
Company News

Medicenna goes public

...million shares at C$2 in a private placement led by Richardson GMP, with participation from Bloom Burton...
BioCentury | Dec 30, 2016
Financial News

Knight Therapeutics completes follow-on

...of 10 million shares at C$10 in a follow-on underwritten by GMP Securities, Cormark Securities, Bloom Burton...
BioCentury | Dec 2, 2016
Emerging Company Profile

Passing CARs

...antigens Disease focus: Cancer Clinical status: Preclinical Founded: 2015 by Jonathan Bramson, Christopher Helsen and Bloom Burton & Co. Inc....
Items per page:
1 - 10 of 93
BioCentury | Aug 28, 2020
Finance

Turning to solid tumors, cell therapy play Triumvira earns syndicate’s $55M vote of confidence

...Andreas Bader, a co-founder of Mirna who worked alongside Lammers.Early investors included Toronto-based investment bank Bloom Burton...
BioCentury | Sep 5, 2019
Financial News

Sept. 5 Financial Quick Takes: Zealand raises cash as it readies NDA; plus Bellus, Aerie, LNC, Veralox and Sigrid

...offering. Underwriters of the offering, upsized from $60 million, are Jefferies, Cowen, Guggenheim, Baird and Bloom Burton...
BioCentury | Sep 4, 2019
Financial News

Sept. 4 Financial Quick Takes: BrightGene looks to STAR; plus IPO updates from Immunotech, 10x Genomics, SpringWorks, IGM, Satsuma and more

...$60 million via an offering of common shares. Underwriters are Jefferies, Cowen, Guggenheim, Baird and Bloom Burton...
BioCentury | Oct 2, 2018
Company News

Management tracks: Synlogic, Trevena, Editas

...named Armand Balboni as its first CSO. He is a partner at investment advisory firm Bloom Burton. BC...
BioCentury | Dec 15, 2017
Financial News

Bellus Health raises C$20M in follow-on

...at C$0.38 in a follow-on. The price values the company at C$45.4 million ($35.4 million). Bloom Burton...
BioCentury | Jun 23, 2017
Financial News

Antibe closes C$4 million follow-on

...the sale of 40.5 million units at C$0.10 in the first close of a follow-on. Bloom Burton...
BioCentury | Jun 23, 2017
Financial News

Resverlogix completes private placement and overnight marketed equity offering

...sold a further 2.6 million units in a concurrent overnight marketed equity offering underwritten by Bloom Burton...
BioCentury | Mar 17, 2017
Company News

Medicenna goes public

...million shares at C$2 in a private placement led by Richardson GMP, with participation from Bloom Burton...
BioCentury | Dec 30, 2016
Financial News

Knight Therapeutics completes follow-on

...of 10 million shares at C$10 in a follow-on underwritten by GMP Securities, Cormark Securities, Bloom Burton...
BioCentury | Dec 2, 2016
Emerging Company Profile

Passing CARs

...antigens Disease focus: Cancer Clinical status: Preclinical Founded: 2015 by Jonathan Bramson, Christopher Helsen and Bloom Burton & Co. Inc....
Items per page:
1 - 10 of 93